The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


FDA Approval of Biopharma's Pain Drug Expected This Year

Research Report
  ()
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. read more >

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation

  ()
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. read more >
News Update

Life Sciences Firm Contracts with Philippines Distributor

News Update
  ()
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. read more >

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates

  ()
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. read more >

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

  ()
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. read more >

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

Research Report
  ()
The events in that trio are presented in a ROTH Capital Partners report. read more >

Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development

  ()
Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations. read more >

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug

  ()
Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZEŽ (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. read more >

Understanding Fortress Biotech

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics. read more >

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

  ()
Insmed Inc.'s shares traded higher after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. read more >

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results

  ()
Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five institutional investors and secured a $30 million non-dilutive term loan facility. read more >

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch

  ()
Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. read more >

Two Approvals Underscore Biotech's Pipeline Quality

Research Report
  ()
The green lights and their implications are discussed in an H.C. Wainwright & Co. report. read more >

California Gold: Two U.S. Hemp Revenue Streams Coming Online This Quarter

Contributed Opinion
  ()
Peter Epstein of Epstein Research discusses recent developments at the company. read more >

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

  ()
Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. read more >

Inovio Pharma Awarded $9M Development Grant for Coronavirus Vaccine

  ()
Inovio Pharmaceuticals' shares rose 30%, setting a new 52-week high price, after the firm reported it received a grant of up to $9 million to develop a vaccine against the coronavirus. read more >

My Prediction for a Market Top in October Was Perhaps Left but Not Wrong

Contributed Opinion
  ()
Bob Moriarty of 321gold reflects on how government actions in the financial and public health spheres will pop market bubbles. read more >

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant

  ()
Neurotrope's shares traded higher after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm was awarded a $2.7 million grant from the National Institutes of Health to conduct additional clinical research for patients with advanced Alzheimer's disease. read more >

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

  ()
Genprex's shares spiked 380% higher as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. read more >

Biopharma Shows 'Good Start to 2020 News Flow'

Research Report
  ()
The two developments that already took place this year are addressed in an H.C. Wainwright & Co. report. read more >

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

  ()
InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. read more >

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

  ()
Shares of NantKwest Inc. spiked as much as 85% higher, setting a new 52-week high price, after the company reported a series of positive results at the 38th JP Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. read more >

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Research Report
  ()
Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. read more >

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

  ()
Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications. read more >

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

  ()
Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. read more >
Showing Results: 1 to 25 of 129 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe